Cargando…

Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India

BACKGROUND & OBJECTIVES: Serosurvey of COVID-19 provides a better estimation of people who have developed antibodies against the infection. Undertaking such a serosurvey in certain districts of India which are densely populated with prominent tribes can provide valuable information regarding ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahapatra, Amarendra, Palo, Subrata Kumar, Bhattacharya, Debdutta, Kanungo, Srikanta, Kshatri, Jaya Singh, Mishra, Bijaya Kumar, Mansingh, Asit, Parai, Debaprasad, Pattnaik, Matrujyoti, Choudhary, Hari Ram, Dash, Girish Chandra, Mohanta, Amiya Ranjan, Bishoyee, Anjan, Mohanty, Prasantajyoti, Mandal, Nityananda, Dayal, Rakesh, Mitra, Anindya, Pati, Sanghamitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057356/
https://www.ncbi.nlm.nih.gov/pubmed/36629182
http://dx.doi.org/10.4103/ijmr.ijmr_3040_21
_version_ 1785016344096276480
author Mahapatra, Amarendra
Palo, Subrata Kumar
Bhattacharya, Debdutta
Kanungo, Srikanta
Kshatri, Jaya Singh
Mishra, Bijaya Kumar
Mansingh, Asit
Parai, Debaprasad
Pattnaik, Matrujyoti
Choudhary, Hari Ram
Dash, Girish Chandra
Mohanta, Amiya Ranjan
Bishoyee, Anjan
Mohanty, Prasantajyoti
Mandal, Nityananda
Dayal, Rakesh
Mitra, Anindya
Pati, Sanghamitra
author_facet Mahapatra, Amarendra
Palo, Subrata Kumar
Bhattacharya, Debdutta
Kanungo, Srikanta
Kshatri, Jaya Singh
Mishra, Bijaya Kumar
Mansingh, Asit
Parai, Debaprasad
Pattnaik, Matrujyoti
Choudhary, Hari Ram
Dash, Girish Chandra
Mohanta, Amiya Ranjan
Bishoyee, Anjan
Mohanty, Prasantajyoti
Mandal, Nityananda
Dayal, Rakesh
Mitra, Anindya
Pati, Sanghamitra
author_sort Mahapatra, Amarendra
collection PubMed
description BACKGROUND & OBJECTIVES: Serosurvey of COVID-19 provides a better estimation of people who have developed antibodies against the infection. Undertaking such a serosurvey in certain districts of India which are densely populated with prominent tribes can provide valuable information regarding seropravelance of SARS-CoV-2 antibodies among such indigenous populations. In this context, two rounds of population-based, cross-sectional serosurveys for SARS-CoV-2 IgG antibody were carried out in Jharkhand, a tribal-dominated State of India, to compare the seroprevalence of SARS-CoV-2 infection and to determine the associated demographic risk factors. METHODS: The surveys were carried out in June 2020 and February 2021 in ten districts of the State of Jharkhand. Blood samples were collected from the residents of the selected districts by random sampling and tested for anti-SARS-CoV-2 antibodies using an automated chemiluminescence immunoassay platform. A total of 4761 and 3855 eligible participants were included in round 1 and round 2, respectively. RESULTS: The age- and gender-standardized seroprevalence for COVID-19 during round 1 was 0.54 per cent (0.36-0.80) that increased to 41.69 per cent (40.16-43.22) during round 2 with a gap of eight months in between. The seropositivity among male and female participants was 0.73 and 0.45 per cent, respectively, during the first round and 51.35 and 33.70 per cent, respectively, during the second round. During the first round, 17.37 per cent of the participants were tribal with seropositivity of 0.24 per cent (0.02-0.87), and during the second round, 21.14 per cent were tribal with seropositivity of 39.14 per cent (35.77-42.59). Compared to tribal group, non-tribal participants had an adjusted odds of 1.24 (95% confidence interval=1.04-1.48) for SARS-CoV-2 seropositivity. INTERPRETATION & CONCLUSIONS: COVID-19 seroprevalence was found to be low during the first round (0.54%) of the survey, possibly due to the travel restrictions during lockdown better adherence to social distancing and wearing of face masks among the people. Understanding the dynamics of SARS-CoV-2 transmission and the susceptibility to infection at the individual as well as community level will inform decision and help policy makers to design and implement effective public health strategies to mitigate the pandemic in this State.
format Online
Article
Text
id pubmed-10057356
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100573562023-03-30 Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India Mahapatra, Amarendra Palo, Subrata Kumar Bhattacharya, Debdutta Kanungo, Srikanta Kshatri, Jaya Singh Mishra, Bijaya Kumar Mansingh, Asit Parai, Debaprasad Pattnaik, Matrujyoti Choudhary, Hari Ram Dash, Girish Chandra Mohanta, Amiya Ranjan Bishoyee, Anjan Mohanty, Prasantajyoti Mandal, Nityananda Dayal, Rakesh Mitra, Anindya Pati, Sanghamitra Indian J Med Res Programme: Original Article BACKGROUND & OBJECTIVES: Serosurvey of COVID-19 provides a better estimation of people who have developed antibodies against the infection. Undertaking such a serosurvey in certain districts of India which are densely populated with prominent tribes can provide valuable information regarding seropravelance of SARS-CoV-2 antibodies among such indigenous populations. In this context, two rounds of population-based, cross-sectional serosurveys for SARS-CoV-2 IgG antibody were carried out in Jharkhand, a tribal-dominated State of India, to compare the seroprevalence of SARS-CoV-2 infection and to determine the associated demographic risk factors. METHODS: The surveys were carried out in June 2020 and February 2021 in ten districts of the State of Jharkhand. Blood samples were collected from the residents of the selected districts by random sampling and tested for anti-SARS-CoV-2 antibodies using an automated chemiluminescence immunoassay platform. A total of 4761 and 3855 eligible participants were included in round 1 and round 2, respectively. RESULTS: The age- and gender-standardized seroprevalence for COVID-19 during round 1 was 0.54 per cent (0.36-0.80) that increased to 41.69 per cent (40.16-43.22) during round 2 with a gap of eight months in between. The seropositivity among male and female participants was 0.73 and 0.45 per cent, respectively, during the first round and 51.35 and 33.70 per cent, respectively, during the second round. During the first round, 17.37 per cent of the participants were tribal with seropositivity of 0.24 per cent (0.02-0.87), and during the second round, 21.14 per cent were tribal with seropositivity of 39.14 per cent (35.77-42.59). Compared to tribal group, non-tribal participants had an adjusted odds of 1.24 (95% confidence interval=1.04-1.48) for SARS-CoV-2 seropositivity. INTERPRETATION & CONCLUSIONS: COVID-19 seroprevalence was found to be low during the first round (0.54%) of the survey, possibly due to the travel restrictions during lockdown better adherence to social distancing and wearing of face masks among the people. Understanding the dynamics of SARS-CoV-2 transmission and the susceptibility to infection at the individual as well as community level will inform decision and help policy makers to design and implement effective public health strategies to mitigate the pandemic in this State. Wolters Kluwer - Medknow 2022-08 2023-01-05 /pmc/articles/PMC10057356/ /pubmed/36629182 http://dx.doi.org/10.4103/ijmr.ijmr_3040_21 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Programme: Original Article
Mahapatra, Amarendra
Palo, Subrata Kumar
Bhattacharya, Debdutta
Kanungo, Srikanta
Kshatri, Jaya Singh
Mishra, Bijaya Kumar
Mansingh, Asit
Parai, Debaprasad
Pattnaik, Matrujyoti
Choudhary, Hari Ram
Dash, Girish Chandra
Mohanta, Amiya Ranjan
Bishoyee, Anjan
Mohanty, Prasantajyoti
Mandal, Nityananda
Dayal, Rakesh
Mitra, Anindya
Pati, Sanghamitra
Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title_full Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title_fullStr Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title_full_unstemmed Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title_short Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India
title_sort trend in seroprevalence of sars-cov-2 (igg antibody) among tribal-dominated population: findings from jharkhand, india
topic Programme: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057356/
https://www.ncbi.nlm.nih.gov/pubmed/36629182
http://dx.doi.org/10.4103/ijmr.ijmr_3040_21
work_keys_str_mv AT mahapatraamarendra trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT palosubratakumar trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT bhattacharyadebdutta trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT kanungosrikanta trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT kshatrijayasingh trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mishrabijayakumar trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mansinghasit trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT paraidebaprasad trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT pattnaikmatrujyoti trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT choudharyhariram trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT dashgirishchandra trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mohantaamiyaranjan trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT bishoyeeanjan trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mohantyprasantajyoti trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mandalnityananda trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT dayalrakesh trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT mitraanindya trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia
AT patisanghamitra trendinseroprevalenceofsarscov2iggantibodyamongtribaldominatedpopulationfindingsfromjharkhandindia